BACKGROUND: To collect oncologists' experience and opinion on adjuvant chemotherapy in elderly breast cancer patients. MATERIALS AND METHODS: A questionnaire was circulated among the members of the Breast International Group. RESULTS: A total of 277 oncologists from 28 countries participated in the survey. Seventy years is the age cut-off commonly used to define a patient as elderly. Biological age and the biological characteristics of the tumor are the most frequently used criteria to propose adjuvant chemotherapy to an elderly patient. Combination therapy with cyclophosphamide, methotrexate and fluorouracil on days 1 and 8 is the most frequently prescribed regimen. Great interest exists in oral chemotherapy. CONCLUSION: There is interest among those who responded to the survey to validate a comprehensive geriatric assessment for use as a predictive instrument of toxicity and/or activity of anticancer therapy and to evaluate the role of a treatment option that is potentially less toxic and possibly as effective as polychemotherapy.
BACKGROUND: To collect oncologists' experience and opinion on adjuvant chemotherapy in elderly breast cancerpatients. MATERIALS AND METHODS: A questionnaire was circulated among the members of the Breast International Group. RESULTS: A total of 277 oncologists from 28 countries participated in the survey. Seventy years is the age cut-off commonly used to define a patient as elderly. Biological age and the biological characteristics of the tumor are the most frequently used criteria to propose adjuvant chemotherapy to an elderly patient. Combination therapy with cyclophosphamide, methotrexate and fluorouracil on days 1 and 8 is the most frequently prescribed regimen. Great interest exists in oral chemotherapy. CONCLUSION: There is interest among those who responded to the survey to validate a comprehensive geriatric assessment for use as a predictive instrument of toxicity and/or activity of anticancer therapy and to evaluate the role of a treatment option that is potentially less toxic and possibly as effective as polychemotherapy.
Authors: Fernando A Angarita; Masanori Oshi; Akimitsu Yamada; Li Yan; Ryusei Matsuyama; Stephen B Edge; Itaru Endo; Kazuaki Takabe Journal: Breast Cancer Res Treat Date: 2022-01-12 Impact factor: 4.872
Authors: Simon Yang; Shabbir M H Alibhai; Erin D Kennedy; Abraham El-Sedfy; Matthew Dixon; Natalie Coburn; Alex Kiss; Calvin H L Law Journal: HPB (Oxford) Date: 2014-06-24 Impact factor: 3.647
Authors: Klaartje Manders; Lonneke V van de Poll-Franse; Geert-Jan Creemers; Gerard Vreugdenhil; Maurice J C van der Sangen; Grard A P Nieuwenhuijzen; Rudi M H Roumen; Adri C Voogd Journal: BMC Cancer Date: 2006-07-06 Impact factor: 4.430
Authors: Ermelinda De Maio; Adriano Gravina; Carmen Pacilio; Gerardo Amabile; Vincenzo Labonia; Gabriella Landi; Francesco Nuzzo; Emanuela Rossi; Giuseppe D'Aiuto; Immacolata Capasso; Massimo Rinaldo; Brunello Morrica; Massimo Elmo; Massimo Di Maio; Francesco Perrone; Andrea de Matteis Journal: BMC Cancer Date: 2005-03-24 Impact factor: 4.430
Authors: Seung Pil Jung; Jeong Eon Lee; Se Kyung Lee; Sangmin Kim; Min-Young Choi; Soo Youn Bae; Jiyoung Kim; Won Ho Kil; Jun-Ho Choe; Jung-Han Kim; Jee Soo Kim; Seok Jin Nam Journal: J Breast Cancer Date: 2012-09-28 Impact factor: 3.588